Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C07K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/139031CRISPR-CAS-BASED COMPOSITION FOR GENE CORRECTION
WO 02.07.2020
Int.Class C07K 14/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Appl.No PCT/KR2019/018627 Applicant INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY Inventor CHOI, Je-Min
The present invention relates to a composition for enhancing the cell permeability and gene correction efficiency of a Cas protein and guide RNA, and in the case of currently used techniques for gene correction through CRISPR-Cas, intracellular injection in a complex form is difficult, stability has not been verified even with injection, efficiency is low, and there are off-target problems. However, when the composition for gene correction according to the present invention is used, the efficiency of intracellular delivery is remarkably high, off-target effects can be inhibited, and stability can be ensured, and thus the composition can be effectively used in gene therapy.
2.WO/2020/139279ACINETOBACTER BAUMANNII BACTERIOPHAGE MIKAB48 OR LYTIC PROTEIN DERIVED FROM THE BACTERIOPHAGE
WO 02.07.2020
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/TR2019/051177 Applicant MIKROLIZ BIYOTEKNOLOJI SAN. VE TIC. LTD. STI. Inventor COTAK, Medine
The invention discloses a novel Acinetobacter baumannii bacteriophage and lytic protein derived from the bacteriophage. The bacteriophage and lytic protein derived from the bacteriophage both have strong in vitro antibacterial effects on pan-drug resistant Acinetobacter baumannii clinical strains providing experimental basis for developing a preparation for preventing and treating infections caused by Acinetobacter baumannii containing the bacteriophage or lytic protein thereof.
3.WO/2020/133233PATHOGENIC MUTATION OF OSTEOGENESIS IMPERFECTA DISEASE AND DETECTION REAGENT THEREFOR
WO 02.07.2020
Int.Class C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
Appl.No PCT/CN2018/124930 Applicant HUANG, Huan Inventor HUANG, Huan
Provided are a pathogenic mutation of osteogenesis imperfecta and a detection reagent therefor. For a mutant COL1A1 gene, single site mutation c.1822G>A (chr17:48270211) is related in the mutated COL1A1 gene, whereof the heterozygous mutation is pathogenic, the genetic mode is dominant inheritance, and for the amino acid change at p.Gly608Ser, the site mutation causes dyssynthesis of I-type collagen in connective tissue, so that a lesion is formed. Provided is a kit for detecting osteogenesis imperfecta, comprising a reagent for detecting the 1822bp-th site of a COL1A1 gene CDS or a reagent for detecting the 608-th amino acid site of a COL1A1 protein. The osteogenesis imperfecta disease can be diagnosed by detecting the pathogenic mutation (c.1822G>A on the COL1A1 gene).
4.WO/2020/133993METHOD FOR POLYPEPTIDE PURIFICATION
WO 02.07.2020
Int.Class C07K 1/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
1General processes for the preparation of peptides
14Extraction; Separation; Purification
Appl.No PCT/CN2019/093680 Applicant HYBIO PHARMACEUTICAL CO., LTD. Inventor YIN, Chuanlong
Provided is a method for polypeptide purification, comprising the following steps: crude purification of a first aqueous two-phase system, refined purification of a second aqueous two-phase system, and reverse phase, gel or ion desalination. The first aqueous two-phase system comprises a first polymer and a first preparation; the second aqueous two-phase system comprises a second polymer and a second preparation; the first polymer or the second polymer is independently selected from polyethylene glycol, polypropylene glycol or glucan; the first polymer or the second polymer may be the same or different; the first preparation is ammonium sulfate, ammonium bicarbonate, ammonium acetate, potassium dihydrogen phosphate, phosphoric acid or sodium chloride; and the second preparation is phosphate, glacial acetic acid, potassium chloride or ammonium acetate. The polypeptide is particularly liraglutide.
5.WO/2020/135201ANTIBODY AND USE THEREOF
WO 02.07.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2019/126495 Applicant SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. Inventor TIAN, Haijun
The present application relates to the field of treatment of diseases, and in particular, to an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Therefore, the present application further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs, wherein the drugs are used for the prevention and/or treatment of tumors.
6.WO/2020/135335MULTISPECIFIC ANTIGEN BINDING PROTEINS CAPABLE OF BINDING CD19 AND CD3, AND USE THEREOF
WO 02.07.2020
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
Appl.No PCT/CN2019/127433 Applicant GENERON (SHANGHAI) CORPORATION LTD. Inventor HUANG, Zhihua
Provided are multispecific antigen binding proteins (MSAPs) that specifically bind to CD3 and CD19. Further provided are uses of the MSAPs for the preparation of pharmaceutical compositions, methods of treating cancer, and kits comprising the MSAPs.
7.WO/2020/135415USE OF ANTI-PD-L1 MONOCLONAL ANTIBODY FOR TREATMENT OF CANCER
WO 02.07.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/CN2019/127891 Applicant CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. Inventor ZHANG, Xiquan
The present application provides use of an anti-PD-L1 monoclonal antibody for treatment of cancer, comprising administering to a subject a therapeutically effective amount of an inhibitor of the interaction between a PD-1 receptor and a ligand PD-L1 thereof, wherein the inhibitor is an anti-PD-L1 monoclonal antibody.
8.WO/2020/136603USE OF ANTI-FAM19A5 ANTIBODIES FOR TREATING ATHEROSCLEROSIS
WO 02.07.2020
Int.Class C07K 16/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
Appl.No PCT/IB2019/061377 Applicant NEURACLE SCIENCE CO., LTD. Inventor KIM, Bongcheol
The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat an atherosclerosis in a subject in need thereof.
9.WO/2020/136060A PEPTIDE-MHC-I-ANTIBODY FUSION PROTEIN FOR THERAPEUTIC USE IN A PATIENT WITH AMPLIFIED IMMUNE RESPONSE
WO 02.07.2020
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/EP2019/086072 Applicant F. HOFFMANN-LA ROCHE AG Inventor KNOETGEN, Hendrik
The present invention relates to a peptide-MHC-I-antibody fusion protein for use as a therapeutic medicament administered to a patient, wherein a cellular cytotoxic immune response towards the virus-derived peptide has been amplified in the patient. The therapeutic medicament may be used in a kit of parts and administered in combination with an amplifying medicament and optionally an inducing medicament. The inducing medicament and the amplifying medicament may be for use in a method of making a patient susceptible for a treatment with the peptide-MHC-I-antibody fusion protein.The medicament(s) may be used for the treatment of diseases, such as cancer or a viral infection.
10.WO/2020/136564PSEUDOFAB-BASED MULTISPECIFIC BINDING PROTEINS
WO 02.07.2020
Int.Class C07K 16/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
Appl.No PCT/IB2019/061304 Applicant SANOFI Inventor BEIL, Christian
Binding proteins comprising a pseudoFab domain including a stabilised knockout domain and a second VH/VL that form a first functional antigen binding domain are provided. Multispecific binding proteins comprising at least one pseudoFab are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.